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Abstract: Left ventricular hypertrophy (LVH) and atrial ﬁ  brillation (AF) are strong predictors 
of cardiovascular (CV) morbidity and mortality, independently of blood pressure levels and other 
modiﬁ  able and nonmodiﬁ  able risk factors. The actions of circulating and tissue angiotensin II, 
mediated by AT1 receptors, play an important role in the development of a wide spectrum of 
cardiovascular alterations, including LVH, atrial enlargement and AF. Growing experimental 
and clinical evidence suggests that antihypertensive drugs may exert different effects on LVH 
regression and new onset AF in the setting of arterial hypertension. Since a number of large 
and adequately designed studies have found angiotensin II receptor blockers (ARBs) to be 
more effective in reducing LVH than beta-blockers and data are also available showing their 
effectiveness in preventing new or recurrent AF, it is reasonable to consider this class of drugs 
among ﬁ  rst line therapies in patients with hypertension and LVH (a very high risk phenotype 
predisposing to AF) and as adjunctive therapy to antiarrhythmic agents in patients undergoing 
pharmacological or electrical cardioversion of AF.
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Introduction
Patients with hypertension are at increased risk of developing a variety of cardiac 
structural and functional changes, such as increased left ventricular (LV) mass, LV 
systolic and diastolic dysfunction, impairment of coronary reserve, left atrial and aortic 
root enlargement, prolonged ventricular repolarization, and arrhythmias (Leonetti et al 
1995; Sega et al 2001; Mitchell et al 2007).
Most attention has been focused on LV hypertrophy (LVH), because of the 
high prevalence of this phenotype and its association with an increased risk of 
cardiovascular morbidity and mortality. Longitudinal observational studies performed 
in general population samples and in hypertensive groups have shown that LVH 
is a robust, independent predictor of sudden death, coronary artery disease, acute 
cerebrovascular events, and congestive heart failure (Levy et al 1990; Koren et al 
1991; Verdecchia et al 2001). A large body of evidence indicates that effective 
antihypertensive treatment can induce LVH regression (Klingbeil et al 2003), improve 
systolic and diastolic LV function (Trimarco et al 1988; Perlini et al 2001) as well 
as reduce ventricular and supra-ventricular arrhythmias (Hennersdorf et al 2001). 
Reversal of LVH has been shown to be associated with a substantial decrease in fatal 
and non fatal cardiovascular complications, including new onset atrial ﬁ  brillation 
(AF) (Okin et al 2006).
Evidence is accumulating that the renin – angiotensin system (RAS) in addition 
to the hemodynamic load plays a pivotal role in the development of hypertensive Vascular Health and Risk Management 2008:4(1) 68
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myocardial hypertrophy and its sequelae. Accordingly, 
the aim of this review is to discuss the current status of 
knowledge concerning the cardioprotective effects of 
angiotensin II receptor blockers (ARBs), focusing on their 
ability to reverse LVH and prevent AF.
The RAS, hypertensive LVH, and AF
Although the pathogenesis of LVH in arterial hypertension 
is not yet fully understood, several lines of experimental 
and clinical evidence indicate that haemodynamic stress 
(ie, pressure and volume overload) is fundamental to 
the development of LVH; a host of nonhemodynamic 
factors, however, substantially contribute to modulating 
the hypertrophic response (Schmieder 2005). In particular, 
activation of the RAS as a consequence of myocardial 
stretch and other stimuli is recognized to play a relevant 
role. In addition to its function in regulating blood pressure 
(BP), angiotensin II, the active component of RAS, by 
acting on type 1 receptors has been shown to stimulate 
various growth factors inducing myocyte hypertrophy and 
myocardial ﬁ  brosis. Although RAS was initially described 
as a circulating system originating in the kidney, many of its 
components have been also localized in tissues such as the 
heart and blood vessels, where they may exert direct effects on 
cardiomyocyte and noncardiomyocyte cells, endothelial and 
vascular smooth muscle cells. Angiotensin II both directly 
and indirectly through aldosterone secretion, has been shown 
to stimulate ﬁ  broblast proliferation, accelerate the turnover of 
ﬁ  brillar collagen, and facilitate deposition of collagen ﬁ  bers 
(Campbell et al 1995). Overall, these processes tend to alter 
tissue structure and increase myocardial stiffness leading 
to diastolic dysfunction, tachyarrhythmias and ultimately 
systolic dysfunction. In hypertensive patients a signiﬁ  cant 
correlation has been shown between the circulating levels of 
angiotensin II (but not plasma renin activity or angiotensin 
I) and several echocardiographic indices of LVH or LV 
concentric remodelling. These ﬁ  ndings result from a number 
of studies showing that patients with inappropriately high 
angiotensin II concentrations in relation to dietary sodium 
intake have a more pronounced LV involvement than 
their counterparts with relatively low angiotensin II levels 
(Schmieder et al 1996). Furthermore, an association has been 
reported between angiotensin II and LV mass, independently 
of ambulatory blood pressure, body mass index and sodium 
excretion values (Schmieder et al 1988; Schlaich et al 
1998). Finally, the LVH phenotype appears to correlate 
with the presence of vascular remodelling and hypertrophy, 
atherosclerotic lesions, increased coagulation and reduced 
ﬁ  brinolysis, namely a series of phenomena also associated 
with RAS activation.
Activation of RAS is also thought to be involved in the 
pathophysiology of AF, and recent data from intervention 
trials suggest that inhibition of RAS might have a role in the 
prevention of AF and its complications. The development and 
persistence of AF are both associated with changes in cardiac 
structure, function and electrical properties known as cardiac 
remodeling. Angiotensin II type 1 receptor stimulation 
induces atrial myocyte hypertrophy, ﬁ  brosis and affects atrial 
contractility leading to atrial structural remodelling (Kaschina 
et al 2003), on the other hand it has been suggested that 
angiotensin II type 2 stimulation counteracts this effect (Rogg 
et al 1996), by inhibiting proliferative processes. Structural 
remodeling in patients with chronic AF is characterized by a 
progressive atrial enlargement and ﬁ  brosis, with histological 
evidence of a large amount of connective tissue between atrial 
myocytes, leading to intra-atrial conduction disturbances 
and persistent electrophysiological inhomogeneities. 
Angiotensin II might also alter atrial electrophysiology by 
modifying ion exchanges within atrial cells: angiotensin 
type 1 receptor stimulation activates phospholipase C, and, 
consequently, via the inositol-triphosphate releases calcium 
from sarcoplasmatic reticulum, the resulting blunted outward 
potassium current leads to increased chamber refractoriness 
(Choudhury et al 2005). Furthermore, polymorphisms of 
RAS gene have been reported to play a role in predisposing 
patients to AF (Tsai et al 2004). Finally, angiotensin II has 
proinﬂ  ammatory and prothrombotic properties that might 
concur to induce a prothrombotic status in AF. The strongest 
argument, however, for a critical role of RAS in AF comes 
from recent clinical trials showing that RAS blockade 
prevents new onset as well as recurrence of AF in different 
clinical settings.
LVH regression: Clinical aspects 
and role of ARBs
The prevalence of echocardiographic LVH is dependent on 
the criteria used for the diagnosis (gender and nongender 
specific, indexed to body surface area or height, more 
or less restrictive) and more importantly on clinical and 
demographic characteristics of the patients examined. In 
uncomplicated never-treated hypertensives the prevalence 
rates of LVH have been reported to range from 15% to 
30% in studies conducted in population-based samples and 
in selected groups of patients referred to specialist centres 
(Sega et al 2001; Cuspidi et al 2002). Higher rates of LVH 
or LV concentric remodeling have been reported in the same Vascular Health and Risk Management 2008:4(1) 69
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settings when other risk factors (ie, metabolic syndrome, 
obesity) were associated to BP elevation (Cuspidi et al 
2004). In treated hypertensives, the prevalence of LVH has 
been reported to span over a very wide range (10%–70%): 
the prevalence is indeed strictly related to clinic and even 
more to ambulatory BP control, to the presence of the above-
mentioned clinical conditions, or to associated CV diseases 
(ie, peripheral artery disease, renal insufﬁ  ciency).
Sustained BP lowering obtained through nonpharmacologic 
and pharmacologic treatment is usually associated with 
substantial reductions in LV mass. Regression of LVH 
during antihypertensive therapy is more closely related 
with the changes in ambulatory BP than with those in ofﬁ  ce 
BP, since the former better reﬂ  ects the overall BP load to 
which the LV is exposed during daily life (Mancia et al 
1997). Thus, reversing LVH is now regarded as an important 
intermediate end-point reﬂ  ecting the protective impact of the 
antihypertensive therapy, since serial changes in LV mass 
have been repeatedly shown to positively correlate with 
fatal and nonfatal CV outcomes in long-term prospective 
observational trials (Verdecchia et al 2003). More direct 
information on this topic has been recently obtained in the 
LIFE echocardiographic substudy, involving 960 patients 
with electrocardiographic LVH. At the end of the 5-year 
study, a decrease of 25 g/m2 (ie, one standard deviation) of 
the LV mass index was associated with a 20% reduction of 
the primary end-point, after adjusting for several potential 
confounders such as type of treatment, basal and treatment 
BP, and basal LV mass index (Devereux et al 2004).
Much of the information on the efﬁ  cacy of one drug class 
over another in decreasing LV mass in hypertensive patients 
is based on a series of meta-analyses published between 
1992 and 2003 (Dahlof et al 1992; Cruickshank et al 1992; 
Schmieder et al 1996; Schmieder et al 1998; Klingbeil et al 
2003). A common feature of all these meta-analyses is that 
they included only echocardiographic studies performed in 
selected hypertensive subjects with preserved LV systolic 
function, without valvular heart disease, cardiomyopathy 
and underlying coronary heart disease. Four meta-analyses 
have suggested that angiotensin-converting enzyme (ACE) 
inhibitors are more effective than other antihypertensive 
agents in reducing LVH, for similar reductions in BP.
However, the most updated meta-analysis indicates 
that ARBs, ACE-inhibitors, and calcium antagonists are all 
more effective in reversing LVH than beta-blockers, while 
the efﬁ  cacy of diuretics is intermediate (Klingbeil et al 
2003). All meta-analysis ﬁ  ndings must be considered with 
caution as many studies included were noncomparative or 
nonrandomized, and often of too small a size. For example, 
of the 109 studies analysed by Dahlof and colleagues (1992) 
less than one ﬁ  fth were randomized, double blind, parallel 
group comparisons. Klingbeil and colleagues (2003) included 
only double blind, randomized, controlled and parallel studies 
in their meta-analysis, however, some of them were small 
(7 patients per treatment arm) and of short duration (4 or 
more weeks).
Because of such limitations meta-analyses cannot offer 
incontrovertible evidence of advantages of speciﬁ  c drug 
classes. Thus, more reliable information is provided by a 
few large and rigorously designed trials performed in the 
last decade. The ﬁ  ndings of these studies indicate that: 
1) BP lowering by whatever agent or agent combination 
is associated with reduction of an increased LV mass; 2) 
ARBs, ACE-inhibitors, and calcium antagonists are similarly 
effective, and more effective than other drug classes. It has 
been speculated that the marked effectiveness of ARBs in 
reversing LVH is related to a more potent and selective RAS 
inhibition. ARBs, indeed, interfere with both ACE and non-
ACE generated angiotensin II. Due to their pharmacological 
properties, they selectively interact with the AT1 receptors 
only, leaving unaffected the AT2 receptors, whose supposed 
antiproliferative actions may be stimulated by the increased 
levels of circulating angiotensin II. Although recent evidence 
obtained in genetically modiﬁ  ed experimental animals does 
not support a direct role of cardiac RAS in LVH (Reudelhuber 
et al 2007), it should be also noted that these findings 
do not rule out a direct role for angiotensin II in cardiac 
remodeling when combined with other humoral, mechanical, 
or pathological stimuli.
To date, more than 60 echocardiographic trials have 
evaluated the effects of the ARBs on LVH in hypertensive 
patients, showing that the selective blockade of AT1 receptors 
results in signiﬁ  cant reductions of LV mass. Among 24 trials 
reviewed by Dahlof and colleagues (2001) including a total 
of 907 patients, only two failed to show signiﬁ  cant effects of 
ARBs on LVH regression. Unfortunately, only few studies in 
Dahlof’s review fulﬁ  lled rigorous methodological criteria, as 
only 11 of them followed a randomized double blind design, 
three lasted more than six months and three included at least 
50 patients per treatment arm.
In this review, we will discuss only the six trials that 
satisﬁ  ed all the above mentioned criteria; keeping in mind, 
however, that the number of 50 patients per treatment-arm is 
less than that required to detect small but clinically relevant 
between-treatment differences in LV mass. Overall, these 
studies involved 1873 patients, randomized to 12 treatment Vascular Health and Risk Management 2008:4(1) 70
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arms: losartan (n = 2), irbesartan (n = 2), candesartan (n = 1), 
valsartan (n = 1), amlodipine (n = 1), enalapril (n = 1), and 
atenolol (n = 4). One study evaluating the effect of irbesartan 
and atenolol treatments during 11 months in 114 patients with 
LVH (LV mass index  131 g/m2 in men and  100 g/m2 
in women) showed that both agents progressively reduced 
LV mass index, the reduction being signiﬁ  cantly greater 
in the irbesartan group (16% vs 9% p   0.01) (Malmqvist 
et al 2000), as well as the proportion of patients with 
normalized LV mass (47% vs 32%). The REGAAL study 
was a 36-week multi-centre study comparing the effect of 
losartan and atenolol (50 mg/day, with possible titration to 
100 mg/day and addition of hydrochlorothiazide) in 225 
patients with LV mass  120 g/m2 and 105 g/m2 in men and 
women, respectively (Dahlof et al 2002). Losartan-based 
regimen signiﬁ  cantly reduced LV mass index from baseline 
(−6.6 g/m2, p   001), whereas atenolol had no signiﬁ  cant 
effect (−3.7 g/m2, p = ns). The CATCH, a European multi-
centre study designed to compare the effects of candesartan 
and enalapril in 239 hypertensives with increased LV mass 
( 120 g/m2 in men and 100 g/m2 in women), demonstrated 
that candesartan and enalapril reduced LV mass index to a 
similar extent (by 15.0 g/m2 and 13.1 g/m2, respectively) 
in comparison to baseline (Cuspidi et al 2002). At the end 
of 48-week treatment, the proportion of patients achieving 
normalization of LV mass index was higher with candesartan 
(36% vs 28 %), although the difference did not achieve 
statistical signiﬁ  cance. In the CardioVascular Irbesartan 
Project 240 patients with essential hypertension (32% of men 
and 42% of women having LVH, according to sex-speciﬁ  c 
criteria of 134/110 g/m2) were treated with irbersartan and 
atenolol for 18 months. A signiﬁ  cant reduction in LV mass 
index was observed only in subjects within the highest 
quartile of baseline LV mass in the irbesartan (−8.4 g/m2) 
but not in the atenolol-treated arm (−3.3 g/m2) (Schneider 
et al 2004). Yasunary and colleagues (2004) evaluated the 
effect of valsartan and amlodipine on LV mass index and 
inﬂ  ammatory markers (reactive oxygen species, C-reactive 
protein) in 104 patients with hypertension and LVH 
(according to the sex speciﬁ  c index of 134/110 g/m2) over 
a period of eight months. Despite similar effects on BP, 
signiﬁ  cant differences on LV mass index were found between 
valsartan and amlodipine treatment (mean decrease 16.0 g/m2 
vs 1.2 g/m2, respectively) as well as on inﬂ  ammatory markers 
(Yasunary et al 2004). The echocardiographic LIFE substudy 
was designed to test the ability of losartan to reduce LV mass 
more than atenolol over a period of 5 years (Devereux et al 
2004). Blinded readings of echocardiograms in 457 loasartan-
treated and 459 atenolol-treated participants were used in an 
intention-to-treat analysis. Losartan-based therapy induced a 
greater reduction in LV mass index from baseline to the last 
available echocardiogram than atenolol after adjustment for 
baseline LV mass index and BP and in-treatment BP (−21.7 
vs −17.7 g/m2, p = 0.02). Greater LV mass reductions with 
losartan were observed in different subgroups: with mild or 
more severe baseline LVH, younger ( 65 years) and older 
participants, women and men.
Prevention of AF and ARBs
AF is the most common cardiac arrhythmia and is strongly 
associated with a substantial risk of stroke and thromboembolism. 
The prevalence of AF increases dramatically with advancing 
age, from 0.1%–0.2% in subjects aged less than 50 years 
to 9%–10% in those over 80 years. AF often coexists with 
hypertension, coronary heart disease, valvular heart disease, 
heart failure, diabetes mellitus and obesity. Currently, 
hypertension is the most prevalent, independent and potentially 
modiﬁ  able risk factor for AF on a population basis (Kannel 
et al 1998). Hypertension may lead to AF through left atrial 
enlargement as a consequence of increased intra-atrial pressure 
driven by reduced LV compliance and LVH. Increased LV 
mass and enlargement of left atrium have been identiﬁ  ed as 
independent determinants of new onset AF (Verdecchia et al 
2003). In population-based studies, AF has been associated 
with a 5–2 times higher risk of death compared with subjects 
free of AF, adjusting for associated cardiac risk factors and 
cardiac disease, and as much as 2.5 time the risk of death in 
hypertensive subjects with LVH.
A large interest has been created by recent studies 
indicating a lower incidence of new and recurrent AF in 
Table 1 Randomized studies comparing the effects of ARBs on 
LV mass in hypertensive patients
Author Drugs  Study  Duration  LV  mass
reference   population  (months)  decrease
   (number)    (g/m2)
Malmqvist et al 2000  Irbesartan  114  11  −26
 Atenolol        −14
Dahlof et al 2001  Losartan  225  9  −6.5
 Atenolol      −3.7
Cuspidi et al 2002  Candesartan  196  10  −15.0
 Enalapril      −13.1
Schneider et al 2004  Irbesartan  240  18  −8.4
 Atenolol      −3.3
Yasunary et al 2004  Valsartan  104  8  −16.0
 Amlodipine      −1.2
Devereux et al 2004  Losartan  960  60  −21.7
 Atenolol      −17.7Vascular Health and Risk Management 2008:4(1) 71
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patients treated with ACE-inhibitors or ARBs. The beneﬁ  cial 
effect of ARBs and ACE-inhibitors in preventing new onset 
or recurrent AF is possibly related to multiple mechanisms. 
Hypertension and heart failure are both associated with RAS 
activation and LV structural alterations; it has been shown that 
treatment of these conditions with ARBs or ACE-inhibitors 
may reduce the risk of AF by preventing or reversing LVH 
and atrial enlargement in the setting of arterial hypertension 
and by slowing the progression of cardiac remodeling in heart 
failure. This is an exciting novel approach to primary and 
secondary prevention of AF, because these drugs, beyond and 
over their BP lowering effect in subjects with hypertension, 
may act on the underlying cardiac structural and electrical 
abnormalities that lead to AF.
Post-hoc analyses of two large hypertension (LIFE and 
VALUE) and two heart failure (CHARM and Val-HeFT) 
trials have reported beneﬁ  cial effects of ARBs on new 
onset AF. The demonstration of favorable effects of these 
agents on AF relapse, however, is based on three small 
prospective studies and on a retrospective analysis of data 
from ACE-inhibitor- or ARB-treated patients with chronic 
heart failure (CHF) or impaired LV function.
In a post-hoc analysis of the LIFE study including 
a total of 8.851 patients on sinus rhythm at the baseline 
electrocardiogram and followed-up for 4.8 years, new onset 
AF was identiﬁ  ed by annual in-study ECGs, analysed in a 
core centre, in 150 patients randomized to losartan versus 221 
patients randomized to atenolol (Wachtell et al 2005); this 
resulted in a 33% relative risk reduction (p   0.001) of new 
onset AF between treatment groups, independent of several 
confounders. Adjustment for difference in ECG LVH and 
Framingham risk score had minimal effects on the lower 
incidence of new AF associated with losartan. Furthermore, 
patients taking losartan tended to stay on sinus rhythm for a 
longer period from baseline than those on atenolol (1809 vs 
1709 days, p = 0.05).
A pre-speciﬁ  ed objective of the VALUE trial was to 
compare the effects of valsartan and amlodipine on new 
onset AF (ie, the incidence of either persistent or at least 
one occurrence of AF) (Schmieder et al 2006). On ECG 
recordings obtained every year, and centrally analyzed for 
ECG–LVH and AF, the incidence of at least one documented 
occurrence of new onset AF was 3.67% in the valsartan 
and 4.34% in the amlodipine treated-arm (odds ratio 0.84, 
p = 0.011). Taking into account potential confounding factors 
as covariates (age, history of coronary artery disease, LVH) 
the incidence of AF persisted signiﬁ  cantly lower in the 
valsartan treated-arm.
In the CHARM program, a large double blind trial aimed 
at evaluating the effects of candesartan on cardiovascular 
mortality and morbidity in a broad spectrum of patients 
with symptomatic chronic heart failure, the incidence of 
new AF was a pre-speciﬁ  ed secondary outcome (Ducharme 
et al 2006). Of the 6446 patients on normal sinus rhythm at 
baseline ECG, 392 (6.08%) developed AF during follow-up, 
177 (5.55%) in the candesartan group and 215 (6.74%) in 
the placebo group, with a relative risk reduction of 19.2%, 
after adjustment for baseline covariates.
The occurrence of AF, based on adverse event reports, was 
evaluated post-hoc in patients with heart failure, randomized 
to valsartan or placebo on top of their prescribed treatments, 
enrolled in the Val-HeFT trial (Maggioni et al 2005). 
During the mean 23 months of follow-up, AF was reported 
in 287/4395 (6.53%) on sinus rhythm at baseline, of whom 
113/2205 were allocated to valsartan, and 174/2190 (7.95%) 
to placebo (−37%, p = 0.0002). Multivariate analyses showed 
that brain peptide levels at baseline, age over 70, male gender 
and the valsartan treatment were independently associated 
Table 2 Randomized studies comparing the effects of ARBs on new-onset or recurrence of AF in different clinical settings
Author Drugs  Study  population  Duration  Incident
reference    (number) and setting  (months)  AF (%)
Watchtell et al 2005  Losartan  8.851   56  3.48 
  Atenolol  HTN and LVH    5.83
Schmieder et al 2006  Valsartan  14849  50  3.67
  Amlodipine  High risk HTN    4.34
Ducharme et al 2006  Candesartan  6446  38  5.55
 Placebo  CHF    6.74
Maggioni et al 2005  Valsartan  4395  23  6.53
 Placebo  CHF    7.95
Madrid et al 2002  Irbesartan  154  8.5  11.3
 Placebo  AF/Cardioversion    29.3
Fogari et al 2006  Losartan  250  12  13
 Amlodipine  HTN+AF    39Vascular Health and Risk Management 2008:4(1) 72
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with AF occurrence. In addition to the previous studies in 
selected patient samples with heart failure and hypertension, 
other studies have examined the effectiveness of RAS 
inhibition in maintaining sinus rhythm. A prospective, 
randomized study including 154 patients with persistent 
AF, showed that addition of irbesartan (150–300 mg/day) 
to amiodarone, 3–6 weeks prior to electrical cardioversion, 
resulted in a lower rate of recurrence of AF than amiodarone 
alone (Madrid et al 2002). In a recent study 250 mild 
hypertensives on sinus rhythm and two documented episodes, 
at least, of symptomatic AF in the previous 6 months and on 
treatment with amiodarone (200 mg/day) were randomized 
to losartan (50–150 mg/day) and amlodipine (5–10 mg/day) 
and were followed up for 1 year (Fogari et al 2006): at least 
one ECG-documented episode of AF was observed in 13% of 
the patients treated with losartan and in 39% of those treated 
with amlodipine (p   0.001).
Finally, in a meta-analysis, including 11 studies (seven 
with ACE-inhibitors and four with ARBs) and 56,308 
patients from different clinical settings, namely heart 
failure (4), hypertension (3), cardioversion after AF (2), 
and myocardial infarction (2) reduction of AF was similar 
between the two class of drugs (ACE-inhibitors −28%, 
p = 0.001, ARBs −29%, p = 0.0002) (Healey et al 2005).
Although recent data on ARBs and AF have generated 
well justiﬁ  ed interest, it must be admitted that there are some 
limitations in the available evidence. Most of the analyses 
have been post-hoc or used AF as secondary or tertiary 
endpoint. AF has been searched on electrocardiograms 
recorded at lengthy intervals. In hypertension trials, a 
placebo-arm was not allowed: it is, therefore, difﬁ  cult to 
conclude whether ARBs did really reduce new onset AF or 
the comparative treatment did increase the chance of AF. 
The two CHF studies used placebo, but in the context of 
multiple and variable background therapy which represented 
an uncontrollable confounding factor. The studies on 
recurrent AF were apparently designed ad hoc, but were 
too small to provide a deﬁ  nite answer. No comparative 
data are yet available, so far, about a direct comparison 
between ARBs and ACEIs. It should be ﬁ  nally underlined 
that speciﬁ  c trials on AF as primary endpoint are ongoing 
and more direct evidence on this issue may be available 
soon (Disertori et al 2006).
Conclusion
Either LVH and AF are strong predictors of cardiovascular 
events, independently of coexistent modiﬁ  able and nonmodi-
ﬁ  able risk factors. The effects of angiotensin II, mediated 
through the AT1 receptor, are critical in the development of 
cardiac structural and functional alterations in combination 
with humoral, mechanical and pathological stimuli.
A growing amount of experimental and clinical data 
suggest that antihypertensive drugs may exert different 
effects on LVH regression and on new onset AF in the 
setting of arterial hypertension. Although more direct 
evidence on the role of ARBs on AF is desirable (and 
hopefully will become available soon), it is reasonable 
to consider this class of drugs among ﬁ  rst line therapies 
in patients with hypertension and LVH (a very high 
risk phenotype predisposing to AF) and as adjunctive 
therapy to antiarrhythmic agents in patients undergoing 
pharmacological or electrical cardioversion of AF. This 
position has also been taken by the recent ESH/ESC 
guidelines on arterial hypertension.
Although the association of an ACE-inhibitor and 
angiotensin receptor antagonist has been reported to exert a 
more pronounced antiproteinuric effect than either component 
alone in diabetic and nondiabetic nephropathy, favorable 
evidence for its use in patients with LVH is lacking, so far. 
The advantages of the full blockade of RAS in reversing LVH 
and preventing AF, as predeﬁ  ned secondary end points, is at 
the present time under investigation in the ONTARGET, an 
international trial comparing an ARB with an ACE-inhibitor 
and their combination in high risk individuals.
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